Drug intelligence / Profile preview

Immunalon

Development stage: Preclinical
Lead developer: Provecs Medical
Modality: Gene Therapies, Vaccines & Immunotherapeutics
Administration: Intravesical, Intratumoral

Overview

Immunalon is an investigational cancer immunotherapy based on Provecs Medical’s ENVIRO adenoviral gene therapy platform, designed to deliver and express up to four immunomodulatory biologics directly within the tumor microenvironment to overcome multiple immune escape mechanisms simultaneously.[2][8][19] By locally reprogramming the tumor milieu and targeting several immune checkpoints and pathways in parallel, this multivalent therapeutic vaccine aims to enhance anti-tumor immune responses across a broad range of solid tumors, with urinary bladder cancer as a lead indication under a development and commercialization partnership with Medac.[2][8][19]

Brand names: Immunalon
Other names: Immunalon

Beyond the preview

Go deeper on Immunalon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunalon.

Explore the full profile